Organon & Co.
Clinical trials sponsored by Organon & Co., explained in plain language.
A global healthcare company focused on women's health and biosimilars.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New cream could help kids with psoriasis Results expected Oct 2026 (estimated)
- New cream could soothe eczema in babies as young as 3 months Results expected Aug 2027 (estimated)
-
Hormone pill tested for prostate troubles – but trial halted early
Disease control Stopped earlyThis phase 2 trial tested a hormone drug called etonogestrel (Org 3236) in 16 men with moderate to severe urinary symptoms from an enlarged prostate. The goal was to see if the drug could shrink the prostate, improve urine flow, and boost quality of life compared to a placebo. Ho…
Phase 2 • Sponsor: Organon and Co • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New birth control pill study halted early – what we know
Disease control Stopped earlyThis study tested a new combined oral contraceptive pill containing nomegestrol acetate and estradiol (NOMAC-E2) to prevent pregnancy. It enrolled over 3,000 women aged 14 to 35 who were at risk of pregnancy and wanted contraception. The trial was terminated early, so final resul…
Phase 3 • Sponsor: Organon and Co • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC